Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAKEI V trial of carboplatin versus cisplatin in extracranial malignant germ cell tumours
2023-507582-25-00Phase 3Authorised
- Sponsor
- University of Bonn
- Start
- Oct 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised trial of carboplatin and cisplatin in extracranial germ cell tumor (EGCT) (2 arms), sponsored by University of Bonn. Primary endpoint: Event-free survival from randomization (EFSr). Planned start Oct 2024; status: authorised.
02
Drugs
carboplatincisplatin
03
Conditions
extracranial germ cell tumor (EGCT)
Beyond the preview
Go deeper on 2023-507582-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507582-25-00.